Platinum Chromium Stent Series – The TAXUS™ Element™ (ION™), PROMUS Element™ and OMEGA™ Stents

Authors:
  • MJMary V Jacoski
    Mary V Jacoski
  • BHBarbara Huibregtse
    Barbara Huibregtse
  • TMTim Mickley
    Tim Mickley
  • KDKeith D Dawkins
    Keith D Dawkins
  • SSSenior Medical Scientist
    Senior Medical Scientist
  • PDPreclinical Sciences Director
    Preclinical Sciences Director
  • RMR&D Senior Manager
    R&D Senior Manager

Abstract
Advances in drug-eluting stent technology have continued to improve clinical outcomes for patients undergoing percutaneous coronary intervention (PCI). The Boston Scientific stent platform has evolved from the 316L stainless steel Express™ stent, to the 316L stainless steel Liberté™ stent, to the cobalt–chromium PROMUS™ stent and, finally, to the platinum–chromium (PtCr) stent series. The PtCr platform, which uses the Element architecture, is designed to have improved deliverability, radiopacity, radial strength and recoil resistance compared with existing stainless steel or cobalt–chromium stents. This review discusses the key points in Boston Scientific’s development programme, which has culminated in the newest generation of coronary stent systems: the PtCr bare-metal OMEGA™ stent, the PtCr paclitaxel-eluting TAXUS Element™ (ION™) stent and the PtCr everolimus-eluting PROMUS Element™ stent systems.